FDA Drug Recalls

Recalls / Class II

Class IID-0269-2023

Product

Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, packaged in (a) 100-count bottle, NDC 68001-501-00; (b) 500-count bottle, NDC 68001-501-03. Manufactured by Alkem Laboratories Ltd., India. For BluePoint Laboratories

Brand name
Metoprolol Succinate
Generic name
Metoprolol Succinate Er Tablets
Active ingredient
Metoprolol Succinate
Route
Oral
NDCs
68001-500, 68001-501, 68001-502, 68001-503
FDA application
ANDA211143
Affected lot / code info
Lots: (a) 21143211, EXP 03/31/2023; (b) 21143185, 21143193, EXP 02/28/2023

Why it was recalled

Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.

Recalling firm

Firm
Amerisource Health Services LLC
Manufacturer
BluePoint Laboratories
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
2550 John Glenn Ave Ste A, N/A, Columbus, Ohio 43217-1188

Distribution

Quantity
(a) 6670 100-count (b) 2666 500-count bottles
Distribution pattern
Nationwide USA

Timeline

Recall initiated
2023-01-11
FDA classified
2023-02-15
Posted by FDA
2023-02-22
Terminated
2024-05-12
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0269-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.